ZIM Laboratories Limited
ZIMLAB · ISIN: INE518E01015
ZIM Laboratories Limited is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE518E01015.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
CHART
ZIM Laboratories Limited - growth of ₹100
Growth of ₹100 invested on 2026-09-30, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-1.04%
3M
+20.84%
6M
+55.26%
1Y
+98.23%
3Y CAGR
+5.48%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
ZIM Laboratories Limited - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.
Technicals
Not available for this stock yet.
Shareholding Pattern
Not available for this stock yet.
Corporate Actions
No corporate actions on record for this stock.
Recent Deals
No recent block/bulk/short-sell deals on record for this stock.
Frequently asked questions
What is ZIM Laboratories Limited's 1-year and 3-year return?
ZIM Laboratories Limited's 1-year price return is +98.23%. Its 3-year CAGR (annualized return) is +5.48%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is ZIM Laboratories Limited's latest financial performance?
ZIM Laboratories Limited's trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹397 Cr, with a TTM profit after tax of ₹4 Cr and an EBITDA margin of null%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹0.82.
Stock data · Not financial advice · Past performance does not indicate future returns